QT interval in patients with primary aldosteronism and low-renin essential hypertension

Journal of Hypertension

Volumn 24, Issue 12, 2006, Pages 2459-2464

  Maule, Simona ^a,b   Mulatero, Paolo ^a   Milan, Alberto ^a   Leotta, Giannina ^a   Caserta, Mimma ^a   Bertello, Chiara ^a   Rabbia, Franco ^a   Veglio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale San Vito   (Italy)

Author keywords

Aldosterone; Aldosteronism; Hypertension; QT interval

Indexed keywords

ALDOSTERONE; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY MONITORING; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; NON INVASIVE MEASUREMENT; PLASMA RENIN ACTIVITY; POTASSIUM CELL LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 33750593780     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000251908.93298.a0     Document Type: Article

References (29)

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
2. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350:1734-1737.
3. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37:429-432.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
5. Pitt B, Remme WJ, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
6. Schouten EG, Dekker JM, Meppelimk P, Kolk FJ, Vanderbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991; 84:1516-1523.
7. Sawicki PT, Dahne R, Bender R, Berger M. Prolonged QT interval as a predictor of mortality in diabetic nephropathy. Diabetologia 1996; 39:77-81.
8. Schwartz PJ, Wolf S. QT interval prolongation as a predictor of sudden death in patients with myocardial infarction. Circulation 1978; 57:1074-1077.
9. Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994; 71:268-273.
10. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005; 16:114-119.
11. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon R, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
12. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6:717-723.
13. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4:1222-1230.
14. Bland MJ, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 8:307-310.
15. Veglio M, Borra M, Stevens LK, Fuller JH, Cavallo Perin P. The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complication Study Group. Diabetologia 1999; 42:68-75.
16. Lim PO, Struthers AD, MacDonald TM. The neurohormonal history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens 2002; 20:11-15.
17. Dekker JM, Schouten EG, Klootwijk P, Pool J, Kromhout D. Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zupthen Study. Circulation 1994; 90:779-785.
18. Oikarinen L, Neiminen MS, Viitasalo M, Toivonen L, Jern S, Dahlof B, et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy. The losartan intervention for endopoint reduction in hypertension study. Hypertension 2004; 43:1029-1034.
19. Blomstrom-Lundqvist C, Caidahl K, Olsson B, Rudin A. Electrocardiographic findings and frequency of arrhythmias in Bartter's syndrome. Br Heart J 1989; 61:274-279.
20. Matsumura K, Fujii K, Kansui Y, Arima H, Iida M. Prolongation of the QT interval in primary aldosteronism. Clin Exp Pharmacol Physiol 2005; 32:66-69.
21. Lorincz I, Matyus J, Zilahi Z, Kun C, Karanyi Z, Kakuk G. QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol 1999; 10:1297-1302.
22. Morris STW, Galiatsou E, Stewart GA, Rodger RSC, Jardine AG. QT dispersion before and after hemodialysis. J Am Soc Nephrol 1999; 10:160-163.
23. Mayet J, Shahi M, McGrath K, Poulter NR, Sever PS, Foale RA, Thom SA. Left ventricular hypertension and QT dispersion in hypertension. Hypertension 1996; 28:791-796.
24. Perkiomaki JS, Ikaheimo MJ, Pikkujamsa SM, Rantala A, Lilja M, Kesaniemi YA, Huikuri HV. Dispersion of QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension 1996; 28:16-21.
25. Mulatero P, Milan A, Williams TA, Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 2006; 4:75-91.
26. Struthers AD. Two new culprits in cardiovascular disease: QT dispersion and aldosterone. J Hum Hypertens 1995; 9:659-661.
27. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001; 3:K70-K80.
28. Marfella R, Rossi F, Giugliano D. Hyperglycemia and QT interval: time for re-evaluation. Diabetes Nutr Metab 2001; 14:63-65.
29. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effect of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001; 37:1800-1807.